Indian Writer's Pursuit of Experimental Depression Therapies Abroad Exposes Systemic Lapses in Domestic Mental Health Provision

In an age wherein the Indian Republic professes universal health coverage yet persistently allocates paltry resources to psychiatric care, the recent odyssey of a former journalist and author, Miss Carly Schwartz, who traversed the Pacific to partake in San Francisco’s most avant‑garde depression treatments, has drawn the attentive eye of both expatriate communities and domestic policy analysts, thereby foregrounding the stark contrast between aspirational policy and lived reality for the nation’s suffering citizens.

Miss Schwartz, whose literary credentials include a memoir chronicling self‑medicated experiments, elected to receive a high‑dose intramuscular injection of ketamine administered by a self‑styled shaman within the modest confines of a Bernal Heights bungalow, an act that, while ostensibly personal, undeniably reflects the paucity of accessible, evidence‑based interventions within India’s public health architecture, compelling those of limited means to seek salvation beyond national borders.

The experimental regimen, complemented by transcranial magnetic stimulation and even an anecdotal fecal analysis purported to calibrate microbiome balance, unfolded under the auspices of private clinics that, in the United States, operate with a regulatory latitude scarcely imagined in the Indian context, thereby exposing a regulatory asymmetry that leaves Indian patients vulnerable to both therapeutic neglect and the allure of unverified remedies.

Observations from Miss Schwartz’s account reveal that the United States facilities, while burdened with their own ethical quandaries, at least maintain a trace of procedural documentation, a stark divergence from the Indian scenario wherein bureaucratic inertia and intermittent policy revisions often result in fragmented service delivery, especially for those residing in rural districts where mental health professionals remain scarce and stigma remains entrenched.

The Indian Ministry of Health, having recently proclaimed a commitment to expand mental health services under the National Mental Health Programme, nevertheless continues to grapple with inadequate funding, insufficient specialist training, and a lack of systematic monitoring of private providers, a combination that arguably drives ambitious yet desperate individuals to foreign shores where experimental therapies are marketed with a veneer of scientific legitimacy, albeit accompanied by costs that render them inaccessible to the majority.

Should the Ministry of Health be compelled to commission independent audits of private psychiatric enterprises that import ketamine and other novel agents without transparent regulatory oversight, thereby ensuring that patients are not reduced to experimental subjects in foreign laboratories, and might such audits be mandated by a legislative framework that obliges the State to substantiate its professed guarantee of mental health as a fundamental right?

May the National Human Rights Commission be urged to delineate clear guidelines obliging both public and private mental health institutions to disclose the evidentiary basis of experimental protocols, to guarantee informed consent that transcends mere procedural formality, and to institute remedial mechanisms for patients who suffer adverse outcomes as a result of unregulated therapeutic excursions?

Could the Supreme Court be called upon to interpret the Constitution’s directive principles concerning health as an enforceable duty upon the State, thus compelling the enactment of comprehensive legislation that curtails the outflow of financially distressed citizens seeking experimental care abroad, while simultaneously mandating robust investment in community‑based mental health infrastructure, training, and research within India’s own borders?

Published: May 11, 2026